[go: up one dir, main page]

MXPA99000214A - Antagonistas de la vasopresina, a base de benzazepinas triciclicas. - Google Patents

Antagonistas de la vasopresina, a base de benzazepinas triciclicas.

Info

Publication number
MXPA99000214A
MXPA99000214A MXPA99000214A MX9900214A MXPA99000214A MX PA99000214 A MXPA99000214 A MX PA99000214A MX PA99000214 A MXPA99000214 A MX PA99000214A MX 9900214 A MX9900214 A MX 9900214A MX PA99000214 A MXPA99000214 A MX PA99000214A
Authority
MX
Mexico
Prior art keywords
vasopressin antagonists
tricyclic benzazepine
compounds
benzazepine vasopressin
exhibit
Prior art date
Application number
MXPA99000214A
Other languages
English (en)
Inventor
Donald Albright Jay
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of MXPA99000214A publication Critical patent/MXPA99000214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a un compuesto triciclico de formula general (I), tal como se define en la presente, el cual exhibe una actividad antagonista en los receptores V1 y/o V2 y exhibe una actividad antagonista en la vasopresina in vivo, a metodos para el uso de esos compuestos en el tratamiento de enfermedades caracterizadas por una reabsorcion renal excesiva del agua, y a procesos para la preparacion de esos compuestos.
MXPA99000214A 1996-06-27 1997-06-20 Antagonistas de la vasopresina, a base de benzazepinas triciclicas. MXPA99000214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/672,150 US5753648A (en) 1995-01-17 1996-06-27 Tricyclic benzazepine vasopressin antagonists
PCT/US1997/010736 WO1997049707A1 (en) 1996-06-27 1997-06-20 Tricyclic benzazepine vasopressin antagonists

Publications (1)

Publication Number Publication Date
MXPA99000214A true MXPA99000214A (es) 2002-07-22

Family

ID=24697350

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA99000214A MXPA99000214A (es) 1996-06-27 1997-06-20 Antagonistas de la vasopresina, a base de benzazepinas triciclicas.

Country Status (13)

Country Link
US (1) US5753648A (es)
EP (1) EP0915876A1 (es)
JP (1) JP2000510154A (es)
KR (1) KR20000022297A (es)
CN (1) CN1231666A (es)
AU (1) AU731925B2 (es)
BR (1) BR9710087A (es)
CA (1) CA2258885A1 (es)
HU (1) HUP0001162A3 (es)
IL (1) IL127470A0 (es)
MX (1) MXPA99000214A (es)
NZ (1) NZ332605A (es)
WO (1) WO1997049707A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987266A4 (en) 1997-03-31 2000-07-26 Wakamoto Pharma Co Ltd BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS
US6235900B1 (en) 1999-02-04 2001-05-22 American Home Products Corporation Tricyclic pyridine N-oxides vasopressin agonists
US6297234B1 (en) 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists
NZ523450A (en) 2000-07-05 2004-11-26 Ortho Mcneil Pharm Inc Nonpeptide substituted spirobenzoazepines as vasopressin receptor antagonists
CN1516589A (zh) 2001-04-12 2004-07-28 用作加压素激动剂的n-联苯羰基-和n-苯基吡啶基羰基取代的二环和三环氮杂�类和二氮杂�类化合物
BR0208824A (pt) 2001-04-12 2004-03-09 Wyeth Corp Composto, métodos de tratamento de distúrbios que são remediados ou aliviados por atividade de agonista de vasopressina em um mamìfero, e de indução de retardamento temporário de urinação em um mamìfero, e, composição farmacêutica
MXPA03010269A (es) * 2001-05-11 2004-05-05 Vertex Pharma Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7119088B2 (en) 2003-02-19 2006-10-10 Pfizer Inc. Triazole compounds useful in therapy
GB0303852D0 (en) * 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
SI1597260T1 (sl) * 2003-02-19 2007-04-30 Pfizer Spojine triazola, uporabne pri terapiji
WO2004080377A2 (en) * 2003-03-11 2004-09-23 Neurosearch A/S Kcnq channel modulating compounds and their pharmaceutical use
PL1633719T3 (pl) * 2003-06-17 2010-03-31 Janssen Pharmaceutica Nv Podstawione spirobenzoazepiny
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
CN101541807A (zh) 2006-09-22 2009-09-23 詹森药业有限公司 用作血管升压素拮抗剂的螺环苯并氮杂
PT2078022E (pt) 2006-09-22 2012-01-11 Janssen Pharmaceutica Nv Espiro benzazepinas utilizadas como antagonistas de vasopressina
BRPI0812504B8 (pt) 2007-06-21 2021-05-25 Cara Therapeutics Inc composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
KR101718384B1 (ko) 2008-06-10 2017-03-22 애브비 인코포레이티드 신규한 트리사이클릭 화합물
DK2506716T3 (en) 2009-12-01 2017-09-04 Abbvie Inc HIS UNKNOWN TRICYCLIC RELATIONS
WO2011068899A1 (en) 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3257291C (en) 2015-10-16 2026-01-06 Abbvie Inc. Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR112020000553A2 (pt) 2017-07-11 2020-07-21 Vertex Pharmaceuticals Incorporated carboxamidas como moduladores de canal de sódio
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766108A (en) * 1986-12-04 1988-08-23 Smith Kline Beckman Corporation Tyr-Arg-vasopressin antagonists
US5055448A (en) * 1987-06-25 1991-10-08 Medical College Of Ohio Linear derivatives of arginine vasopressin antagonists
DE69009785T2 (de) * 1989-02-10 1994-11-03 Otsuka Pharma Co Ltd Carbostyrilderivate.
EP0450097B1 (en) * 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5070187A (en) * 1989-11-03 1991-12-03 Trustees Of Boston University Pharmacologically effective antagonists of arginine-vasopressin
TW199153B (es) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk
CA2066104C (en) * 1991-04-19 2003-05-27 Hidenori Ogawa Benzazepine derivatives as vasopressin antagonists
EP0533240A3 (en) * 1991-09-16 1993-09-29 Merck & Co. Inc. Substituted amine derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
US5204349A (en) * 1991-09-16 1993-04-20 Merck & Co., Inc. Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
DE69223573D1 (de) * 1991-09-16 1998-01-29 Merck & Co Inc Hydantoin und Succinimid-substituierte Spiroindanylcamphorsulfonyl als Oxytocin-Antagonisten
EP0533242A3 (en) * 1991-09-16 1993-09-15 Merck & Co. Inc. Substituted derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
AU657431B2 (en) * 1992-08-20 1995-03-09 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds as oxytocin and vasopressin antagonists
WO1994012476A1 (fr) * 1992-11-25 1994-06-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de benzanilide
WO1994014796A1 (fr) * 1992-12-21 1994-07-07 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de n-(pyridylcarbonyl)benzazepine et son intermediaire
WO1994020473A1 (fr) * 1993-03-11 1994-09-15 Yamanouchi Pharmaceutical Co., Ltd. Compose avec action antagoniste de la vasopressine
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists

Also Published As

Publication number Publication date
IL127470A0 (en) 1999-10-28
HUP0001162A3 (en) 2001-02-28
HUP0001162A2 (hu) 2000-09-28
US5753648A (en) 1998-05-19
WO1997049707A1 (en) 1997-12-31
CA2258885A1 (en) 1997-12-31
JP2000510154A (ja) 2000-08-08
EP0915876A1 (en) 1999-05-19
NZ332605A (en) 2000-09-29
BR9710087A (pt) 1999-08-10
CN1231666A (zh) 1999-10-13
AU731925B2 (en) 2001-04-05
AU3406397A (en) 1998-01-14
KR20000022297A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
MX9705313A (es) Benzazepinas triciclicas antagonistas de la vasopresina.
MXPA99000214A (es) Antagonistas de la vasopresina, a base de benzazepinas triciclicas.
MX9705415A (es) Antagonsitas de vasopresina triciclicos de benzazepina.
IL110436A0 (en) Tricyclic benzazepine vasopressin antagonists
EA199700116A1 (ru) Трициклические бензазепины как антагонисты вазопрессина, способ их получения, фармкомпозиция на их основе и способ лечения
IL149550A0 (en) Bicyclic and tricyclic heteroaromatic compounds
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
NZ519241A (en) Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
MX9702865A (es) Agentes estrogenicos.
MX9805253A (es) Antagonistas del receptor de vitronectina.
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
IL116406A0 (en) Tricyclic substituted hexahydrobenz (e) isoindole alpha-1 adrenergic antagonists
IL142893A0 (en) Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
YU75101A (sh) Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa
MY133390A (en) Azabicyclic 5ht1 receptor ligands
HUP0001165A3 (en) Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists, pharmaceutical compositions containing them and process for producing them
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
MX9801179A (es) Isoquinolinas fusionadas, novedosas como ligandos del receptor de dopamina.
GR3032950T3 (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
MY118704A (en) Process for preparation of eprosartan
CA2210631A1 (en) Tricyclic benzazepine vasopressin antagonists
GB9906882D0 (en) Organic compounds
ES2141671A1 (es) Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
MX9710389A (es) Antagonistas del receptor de vitronectina, su preparacion y empleo del mismo.